Fleming Harold Edward 4

What Happened

• Harold Edward Fleming, a director of Sionna Therapeutics, was granted a derivative award covering 17,340 shares on June 17, 2026. The award is reported at $0.00 (no cash paid) and is recorded as a derivative/acquisition (code A) rather than an open‑market purchase.

Key Details

• Transaction date: 2026-06-17; SEC filing date: 2026-06-18 (timely).
• Grant size: 17,340 shares; reported price: $0.00 (derivative award/option-style grant).
• Vesting: vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting, subject to continued service.
• Beneficial ownership: Fleming agreed to receive and hold the securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title and interest in the option and shares issuable upon exercise.
• Shares owned after the transaction: not directly reported for Fleming (ownership is disclaimed in favor of Enavate Sciences, LP).

Context

• This filing reflects an award/option grant (derivative) rather than a cash purchase or immediate sale; the award vests in the future and does not indicate an immediate change in market holdings by Fleming personally. Because Fleming disclaims beneficial ownership, the economic interest appears tied to Enavate Sciences, LP rather than the individual director.